$6.02
▲ +0.2% Today
as of Sep 4, 16:55 ET
Last 30 days
Recent Press Releases & News
Upstream Bio on Track to Begin Two Phase 3 Verekitug Trials in Q1 2027
Upstream Bio Announces Pivotal Phase 3 Development Plans for Verekitug in Both Severe Asthma and CRSwNP
Upstream Bio, Inc. (UPB) Reports Q2 Loss, Tops Revenue Estimates
Overview
52-week range
$5.77
$34
1% of range
Avg surprise (last 3)
-6.4%
Avg reaction (last 2)
-0.4%
50% positive
Latest IV / EM
51%
EM ±8.5% · $8 · Sep 18
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue Jun 30, 2026 | Jun 2026 | $-0.73 | — | — | — | — | financials |
| Wed May 13, 2026 | Mar/2026 | $-0.75 | $-0.80 | +6.2% | -47.1% | +4.6% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.63 | — | — | — | — | financials |
| Wed Aug 6, 2025 | Jun/2025 | $-0.74 | $-0.61 | -21.3% | — | — | earnings |
| Tue May 6, 2025 | Mar/2025 | $-0.51 | $-0.49 | -4.1% | — | -5.4% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-6.96 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-6.50 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-4.68 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-2.11 | — | — | — | — | financials |
Financials
Income statement (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $773,000 | $1M | — | $683,000 | $937,000 | $566,000 | — | $607,000 |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-42M | $-44M | — | $-38M | $-44M | $-32M | — | $-19M |
| Net income | $-40M | $-41M | — | $-34M | $-40M | $-27M | — | $-16M |
| EPS (diluted) | $-0.73 | $-0.75 | — | $-0.63 | $-0.74 | $-0.51 | — | $-6.96 |
Balance sheet (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $79M | $97M | $102M | $72M | $45M | $71M | $326M | $33M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $280M | $316M | $352M | $389M | $418M | $454M | $479M | $227M |
| Total assets | $281M | $318M | $354M | $391M | $421M | $456M | $482M | $233M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $10M | $14M | $14M | $13M | $12M | $11M | $12M | $12M |
| Total equity | $271M | $304M | $340M | $379M | $409M | $446M | $470M | $-160M |